Dai L.-P.,Henan University of Traditional Chinese Medicine |
Dai L.-P.,Chinese Institute of Materia Medica |
Dai L.-P.,Collaborative Innovation Center for Respiratory Disease Diagnosis and Treatment |
Li C.,Chinese Institute of Materia Medica |
And 9 more authors.
Molecules | Year: 2015
Three types of ent-kaurane diterpenoids were isolated from the aerial parts of Isodon excisoides, including three new diterpenoids, 1α,7α,14β-trihydroxy-20-acetoxy-entkaur- 15-one (1); 1α,7α,14β,18-tetrahydroxy-20-acetoxy-ent-kaur-15-one (2); and 1α-acetoxy- 14β-hydroxy-7α,20-epoxy-ent-kaur-16-en-15-one (3); together with six known diterpenes henryin (4); kamebanin (5); reniformin C (6); kamebacetal A (7); kamebacetal B (8); and oridonin (9). The structures of the isolated compounds were elucidated by means of nuclear magnetic resonance spectroscopy and high-resolution mass spectrometry in conjunction with published data for their analogs, as well as their fragmentation patterns. Compounds 5 and 9 were isolated from Isodon excisoides for the first time. To explore the structure-activity relationships of the isolated compounds, they were tested for their cytotoxic effects against five human cancer cell lines: HCT-116, HepG2, A2780, NCI-H1650, and BGC-823. Most of the isolated compounds showed certain cytotoxic activity against the five cancer cell lines with IC50 values ranging from 1.09-8.53 μM. Among the tested compounds, compound 4 exhibited the strongest cytotoxic activity in the tested cell lines, with IC50 values ranging from 1.31-2.07 μM. Compounds 1, 6, and 7 exhibited selective cytotoxic activity. © 2015 by the authors; licensee MDPI, Basel, Switzerland.
Haifeng W.,Henan University of Traditional Chinese Medicine |
Haifeng W.,Collaborative Innovation Center for Respiratory Disease Diagnosis and Treatment |
Hailong Z.,Henan University of Traditional Chinese Medicine |
Hailong Z.,Collaborative Innovation Center for Respiratory Disease Diagnosis and Treatment |
And 12 more authors.
Complementary Therapies in Medicine | Year: 2015
Objective: This study was intended to evaluate the efficacy and safety of Traditional Chinese Medicine (TCM) on stable chronic obstructive pulmonary disease (COPD). Method: A systematic review was conducted of clinical trials that compared TCM plus conventional medicine treatment versus conventional medicine treatment alone. Randomized controlled trials (RCTs) of clinical therapeutic studies on COPD by TCM were included. Searches were applied to the following electronic databases: The PubMed[U+3001] the Cochrane Library[U+3001]CNKI[U+3001]CBM and VIP. No blinding and language restriction was used. All trials included were analyzed according to the criteria of the Cochrane Handbook. Review Manager 5.2 software was used for data analysis. Result: 37 randomized clinical trials enrolling 3212 patients were included. Follow-up duration ranged from 4 weeks to 1.5 years. Compared to conventional medicine treatment alone, TCM plus conventional medicine treatment showed improvement in forced expiratory volume in one second (FEV1) (MD 0.12 L; 95% CI 0.08 to 0.16), and less exacerbation (OR -0.86; 95% CI -1.13 to -0.60). TCM treatment also led to a statistically improvement in SGRQ score compared to placebo (MD -4.36; 95% CI -7.12 to -1.59). There was statistically significant difference in six-minute walk distance (MD 36.66 meters, 95% CI 24.57 to 48.74) found with TCM compared to placebo. Conclusion: Among patients with stable COPD, TCM plus conventional medical treatment therapy might be associated with reduction risk of exacerbation, improvement of lung function, better quality of life and higher exercise capacity. The results were limited by the methodological flaws of the studies. High quality studies are needed to provide clear evidence for the future use of TCM. © 2015 Elsevier Ltd.
Comparison of conventional medicine, TCM treatment, and combination of both conventional medicine and TCM treatment for patients with chronic obstructive pulmonary disease: Study protocol of a randomized comparative effectiveness research trial
Li J.-S.,Henan University of Traditional Chinese Medicine |
Li J.-S.,Collaborative Innovation Center for Respiratory Disease Diagnosis and Treatment |
Xie Y.,Henan University of Traditional Chinese Medicine |
Xie Y.,Collaborative Innovation Center for Respiratory Disease Diagnosis and Treatment |
And 4 more authors.
Trials | Year: 2014
Background: Chronic obstructive pulmonary disease (COPD) affects millions worldwide. Although many therapies exist and are being developed to relieve symptoms and reduce mortality, few data are available to understand which of the therapeutic alternatives is the most cost-effective for COPD patients in everyday clinical practice, especially for traditional Chinese medicine (TCM). Comparative effectiveness research can help patients, clinicians, and decision-makers make best informed treatment decisions where such evidence was previously lacking. This study aims to compare the effectiveness and economic evaluation of three treatments: (1) conventional Western medicine; (2) TCM treatments, which have been evaluated and have certain effect; and (3) a combination of both conventional Western medicine and TCM treatments, and then determine which treatment is the most suitable for COPD patients.Methods/design: A multicenter, pragmatic, randomized, controlled trial is adopted. A total of 360 patients will be recruited and randomly assigned to one of the three treatments group, with 120 in each group. Patients in the conventional Western medicine group will be given Salbutamol, Formoterol, Salmeterol/fluticasone, respectively, according to the guidelines. For the TCM group, patients will be given Bufei granule, Bu-Fei Jian-Pi granule, Bu-Fei Yi-Shen granule, and Yi-Qi Zi-Shen granule based on their corresponding TCM syndrome patterns, respectively. For the combination of conventional medicine and TCM treatments group, patients will be given a combination of conventional Western medicine and TCM granules. Treatments in each group are recognized as a whole comprehensive intervention. After the 26-week treatment, another 26 weeks will be followed up. The outcome measures including the frequency and duration of acute exacerbations, lung function, dyspnea, exercise capacity, quality of life, and economic evaluation will be assessed.Discussion: It is hypothesized that each of the three treatments will have beneficial effects in reducing the frequency and duration of acute exacerbations, improving exercise capacity and psychosocial function of COPD patients. In addition, the combination of conventional medicine and TCM treatments may be most suitable for COPD patients with better effectiveness and economic evaluation.Trial registration: ClinicalTrials.gov NCT01836016. © 2014 Li et al.; licensee BioMed Central Ltd.
Li M.,Heilongjiang University of Chinese Medicine |
Li M.,Collaborative Innovation Center for Respiratory Disease Diagnosis and Treatment |
Wang X.,Collaborative Innovation Center for Respiratory Disease Diagnosis and Treatment |
Wang X.,Henan University of Traditional Chinese Medicine |
And 15 more authors.
Molecules | Year: 2015
A new ionone glycoside, frehmaglutoside I (1), and three new rhemaneolignans A-C (2-4) were isolated from the 95% EtOH extract of the roots of Rehmannia glutinosa. Their structures were determined by extensive spectroscopic (UV, IR, HR-ESI-MS, 1D and 2D NMR) analyses. In addition, these compounds were evaluated for their protective effects on cardiocytes impaired by doxorubicin in H9c2 cells. Among them, compounds 1-3 exhibited protective effects against DOX-induced cardiotoxicity. © 2015 by the authors.